Six poster presentations at last month’s British HIV Association (BHIVA) Conference in Brighton found that only a minority of people with HIV are being offered and starting to take the ...

Letermovir, an antiviral drug for cytomegalovirus (CMV), was associated with reduced inflammation, improved CD4/CD8 T-cell ratios and better physical function for people with HIV on effective ...

It’s rare in any branch of medicine that a trial of a new drug can report 100% efficacy, and a first in HIV science. But that’s what happened on Friday, when Gilead Sciences announced that no HIV ...

A CRISPR-based gene-editing therapy called EBT-101 was safe and well tolerated but did not prevent viral rebound in three participants who stopped antiretroviral treatment in an early study, according ...

A longer-acting formulation of cabotegravir may offer an HIV pre-exposure prophylaxis (PrEP) and treatment option that could be administered once every four months, according to early study results ...

A once-weekly oral regimen can keep HIV suppressed as well as daily pills, according to study results presented today at the Conference on Retroviruses and Opportunistic Infections (CROI 2024).. In a ...

A waxy substance, mostly made by the body and used to produce steroid hormones. High levels can be associated with atherosclerosis. There are two main types of cholesterol: low-density lipoprotein ...

In some cases, HIV can bypass the barrier that encases the brain and cerebrospinal fluid which can contribute to brain inflammation and neurocognitive symptoms. However, diagnosing this viral ‘escape’ ...

HIV diagnoses rose in England in 2022, but much of the increase was due to the arrival of people with HIV already on antiretroviral treatment rather than an increase in HIV transmission, the UK Health ...

An HIV vaccine candidate has proved it can guide B-cells, the part of the immune system that makes antibodies, into being able to produce broadly neutralising antibodies (bnAbs) with the ability to ...

But injectable HIV treatment could have a future in the global south, particularly when other long-acting products are developed, experts said at the 12th International AIDS Society Conference on HIV ...

Findings from the landmark REPRIEVE trial, which tested a daily statin medication for people living with HIV, were presented on Monday at the 12th International AIDS Society Conference on HIV Science ...